Representative clinical trials: better science through broader participation

Generalisability begins with who takes part. Treatments are ultimately used by patients of every age, background and health profile — so evidence serves best when trial populations reflect that reality. As a 2023 perspective in the New England Journal of Medicine argues, diverse participation matters for generating knowledge that applies broadly, for fairness, and for the trust on which research depends.^[1]

Why gaps arise — and how design closes them

Under-representation rarely stems from unwillingness; it accumulates from practical friction — distance to sites, work and caring commitments, language, and narrow eligibility rules that exclude common real-world patients. The encouraging news is that each barrier has a design answer:

• Eligibility that mirrors practice. Reviewing exclusion criteria against clinical reality often widens who can safely join.
• Participation made practical. Decentralised elements — local visits, telehealth, flexible scheduling — remove the frictions that filter out ordinary lives; the FDA’s 2024 decentralisation guidance explicitly notes their potential to broaden access to trials.^[2]
• Community partnership. Working with trusted local clinicians and organisations builds bridges long before recruitment begins.
• Measure representativeness. Tracking enrolment against the intended-use population turns aspiration into a managed study outcome.

The translational payoff

Representative evidence travels further: clinicians apply results with more confidence, health systems adopt with fewer caveats, and the bench-to-bedside-to-community arc that defines translational medicine completes for more patients.

How the gap arose — and why it matters scientifically

The under-representation challenge accumulated honestly: trials clustered around academic centres, eligibility criteria written for safety narrowed populations further, and the practical burdens of participation — travel, time, language — filtered out everyone whose life could not absorb them. The result, documented repeatedly across therapy areas, is evidence generated in populations measurably younger, healthier and less diverse than the patients who ultimately use the medicines. The scientific cost is concrete: dosing insights missed where pharmacogenetic variation differs across ancestries, safety signals diluted, effect estimates of uncertain portability — and clinicians left extrapolating precisely for the patients about whom evidence is thinnest.

The policy environment has now firmly turned. Regulators increasingly expect enrolment plans that reflect the intended treatment population, and sponsors publish diversity commitments — recognition that representativeness is not a social courtesy appended to science, but a dimension of scientific validity itself.

What actually moves enrolment

• Eligibility criteria audited for necessity. Many exclusions persist by template rather than rationale; systematically challenging each one widens eligibility without compromising safety.
• Sites where the patients are. Partnering with community hospitals and primary-care networks — supported with infrastructure and training — reaches populations academic centres structurally miss.
• Burden engineered down. Decentralised elements, evening visits, travel support and translated materials convert willingness into actual participation.
• Trusted messengers. Community organisations and clinicians who already hold relationships outperform any recruitment advertisement — and partnership must precede the ask.
• Measurement with accountability. Enrolment tracked against epidemiology in real time, with course corrections during the trial, not regrets after it.

Looking ahead

Representative research is becoming an operational discipline with its own evidence base — what works, at what cost, in which settings — rather than an aspiration paragraph. The direction of travel benefits everyone: sponsors gain generalisable evidence and faster recruitment from wider pools; health systems gain trial access as a component of care; and patients gain medicines tested in populations that actually resemble them. It is that rare policy area where scientific quality and fairness point the same way.

Where EUSTM fits

The EUSTM Academy’s Professional Certification in Clinical Research (PCCR) embeds these design fundamentals within recognised professional competence for research teams worldwide.

Disclaimer. This Expert Insight is provided by EUSTM for general informational and educational purposes only. It does not constitute medical, clinical, legal, regulatory or other professional advice, and it should not be relied upon as the basis for clinical, regulatory or business decisions. While care is taken in preparing this content, EUSTM makes no representation or warranty as to the accuracy, completeness or currency of any scientific, medical or other statements, and accepts no liability arising from the use of this content. Readers should consult the cited sources, the current official guidance of the relevant authorities and frameworks, and appropriately qualified professionals in their own jurisdiction. References to third-party organisations, publications or frameworks are for information only and do not imply affiliation or endorsement.

← All Expert Insights